Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2026Frontiers in ImmunologyOpen Access

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNadia MazarakisRoyal Children's HospitalZTZheng Quan TohThe University of MelbourneTBTsetsegsaikhan BatmunkhNational Center for Communicable Diseases

Discussion

Loading...

Member takes

Implication

Randomized trial examines long-term immune responses post-standard and fractional BNT162b2 booster in adults, indicating effective dosing strategies.

Key Points

  • To evaluate long-term cellular immune responses to fractional versus standard doses of BNT162b2 in adults.
  • Randomized controlled trial with N=601 participants, primed with different vaccines and assigned to either 15 μg or 30 μg BNT162b2 booster doses.
  • Immune responses measured at 12 months post-vaccination, focusing on antibody levels and T-cell responses.
  • Subgroup analysis involved 256 participants for cell-mediated immunity assessment.
  • At 12 months, both booster doses maintained IgG levels 1.7–2.7-fold higher than baseline.
  • Neutralizing antibodies showed 89% inhibition across both dosing groups.
  • Total AIM and ICS T-cell responses remained similar between groups, revealing robust immunity against wild-type and JN.1 variants.

Cite This Study

Mazarakis et al. (2026) studied this question.

synapsesocial.com/papers/69edaafc4a46254e215b3378https://doi.org/10.3389/fimmu.2026.1779435
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD12222022 · 7 citations
  2. 2Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster2024 · 27 citations
  3. 3XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.12024 · 184 citations
  4. 4Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays2023 · 4 citations
  5. 5Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial2021 · 699 citations